Rhumbline Advisers Has $647,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Rhumbline Advisers increased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 14.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 47,860 shares of the company’s stock after purchasing an additional 5,990 shares during the quarter. Rhumbline Advisers owned approximately 0.09% of Stoke Therapeutics worth $647,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in STOK. Nisa Investment Advisors LLC increased its position in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Stoke Therapeutics during the 2nd quarter valued at about $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics during the 1st quarter valued at about $141,000. BNP Paribas Financial Markets increased its position in Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares in the last quarter. Finally, Chase Investment Counsel Corp acquired a new stake in Stoke Therapeutics in the 1st quarter valued at about $279,000.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Insider Buying and Selling

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the completion of the sale, the insider now owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The disclosure for this sale can be found here. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $12.86 on Wednesday. Stoke Therapeutics, Inc. has a one year low of $3.35 and a one year high of $17.58. The company has a market cap of $670.28 million, a P/E ratio of -5.34 and a beta of 0.96. The firm’s fifty day moving average price is $14.44 and its two-hundred day moving average price is $13.28.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.